Prostate Cancer

Testosterona y anabólicos causan graves daños a la salud. Foto: Pixabay CIUDAD DE MÉXICO.  El titular del servicio de Endocrinología del Hospital de Especialidades del IMSS en Jalisco, Miguel Escalante Pulido, advirtió sobre el uso de testosterona y anabólicos para ganar masa muscular. Apuntó que el deseo de ganar masa muscular con menor esfuerzo y en poco tiempo lleva a hombres y mujeres a buscar alternativas como el uso de la hormona testosterona y anabólicos (derivados sustitutos de la misma hormona), lo cual puede ser perjudicial para su salud . Van al gimnasio y se ponen cantidades altísimas de testosterona, de hecho, hay mujeres que también se androgenizan utilizando esta hormona, y el abuso de estas sustancias conlleva diversas contraindicaciones y potenciales daños a la salud”, explicó. Manifestó que hay casos de cáncer hepático, prostático y daño renal agudo , “el objetivo de ingerir esto es tener masa muscular con menor esfuerzo”. Puntualizó que antes de ...

Acabamos de pasar octubre “rosa” y con él las celebraciones y campañas dirigidas a todas las mujeres de prevención de cáncer de mama, el de mayor incidencia entre el sexo femenino. Pero, ¿qué nos depara noviembre? Te puede interesar:  Rascarse los testículos puede prevenir el cáncer Desde hace 15 años, durante este mes, los hombres dejan crecer sus bigotes y barbas para concientizar a la sociedad sobre el cáncer de próstata, testículos y salud mental. Temas que aún no está tan socializados como el de otras enfermedades. Y es que, según la Fundación Movember, organización que da nombre a este movimiento, este tipo de cáncer es el segundo más común en afectar al sexo masculino en todo el mundo y del que se espera que en 2030 se duplique el número de casos hasta los 1,7 millones. “En muchas ocasiones este tipo de enfermedades es aún un tabú, de las que da pena hablar o de las que creemos que nunca nos pasarán a nosotros, estando totalmente equivocados con esto” afirma el Dr. Elía...

First there were tests, then a biopsy, and finally a diagnosis: “You have prostate cancer.” How could anyone plan for this moment? Questions that immediately came to mind were what stage am I, what are the chances of whatever path I take working, and what will the side effects be? “Cured” was a word I read men with prostate cancer will never hear. I was told I was not the typical prostate cancer patient as I was too young, in good health, ate well, didn't smoke, and didn't drink alcohol. I thought to myself, what could I have possibly done differently? How about not having a brother with the disease a year earlier? Continue Reading Below I underwent a robotic prostatectomy in 2009. Five years later my cancer was back with external radiation treatments being my best option, but even that had only a 50% chance of working. I wondered how this could happen, because after my surgery, I had only a 15% chance of my cancer coming back in the next 10 years. Two doctors told me t...

October 29, 2018 Share this content: Radiotherapy may improve survival among men with low metastatic burden. Adding radiotherapy to standard-of-care androgen deprivation therapy (ADT) did not improve survival in men with newly diagnosed metastatic prostate cancer , according to the results of the STAMPEDE trial. 1 Compared with standard of care, radiotherapy improved failure-free survival (hazard ratio [HR] = 0.76; 95% confidence interval [CI], 0.68-0.84; P < .0001), but did not improve overall survival (HR = 0.92; 95% CI, 0.80-1.06; P = .266). Continue Reading Below However, a subgroup analysis showed that overall survival was improved in those patients with a low metastatic burden at baseline assigned to radiotherapy (HR = 0.68; 95% CI, 0.52-0.90; P = .007). Three-year survival in these men was 81% with radiotherapy compared with 73% in the standard-of-care group. These results support findings from a previous study that showed that survival might be improved in pat...

NEW YORK (GenomeWeb) – Epic Sciences and Genomic Health said today that Medicare Administrative Contractor Palmetto GBA has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test, which was developed and continues to be performed by Epic Sciences. Palmetto released its draft LCD for the test this March. The final determination recommends limited coverage for use of the test throughout the US to help determine which patients with metastatic castrate-resistant prostate cancer may benefit from continued androgen receptor signaling inhibitor therapy — using drugs like enzalutamide, abiraterone, and apalutamide — and which may be better served by chemotherapy. The assay uses Epic's "No Cell Left Behind" circulating tumor cell analysis platform to identify AR-V7 positivity in CTC nuclei. Genomic Health partnered with Epic in 2016 to bring the assay to market, and launched it commercially this February. Studies of the test...

MANHATTAN BEACH, CA – During the month of November, some members of Manhattan Beach Police Department will be growing and showing mustaches and mustache pins to show their support for prostate cancer awareness as part of the Movember campaign. The annual event involves growing moustaches during the month of November to raise awareness of prostate cancer. The goal of Movember is to "change the face of men's health," MBPD said. "Movember aims to increase early cancer detection, diagnosis and effective treatments, and ultimately reduce the number of preventable deaths," police said. "Men are encouraged to be aware of any family history of cancer and to adopt a healthy lifestyle." The Manhattan Beach Police Department is proud to be part of this movement to generate awareness for those whose lives have been affected by prostate cancer, according to MBPD. For more information visit their website . Image via Manhattan Beach Police Department Get the ...